When CLL cells carrying mutations in the BTK gene (C481S or C481F mutation) were subjected to treatment with NC‐1, there was a decrease in BTK, as well as a reduction in the activation of the respective downstream elements (Akt and ERK).117. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.